Syngene International Limited

94%

expert, My Green Lab (MGL), earned the highest level ‘Green Certification’ with a score exceeding 94%. Further, Syngene strengthened its position as a global sustainability leader, with its EcoVadis 2

Rs 911

nking it among the top companies worldwide for sustainability practices.. Revenue from Operations Rs 911 Cr ( 2% Y-o-Y) ~USD 103 Mn Operating EBITDA margin 22% (27% in Q2 FY25) Reported PAT before excep

2%

ng the top companies worldwide for sustainability practices.. Revenue from Operations Rs 911 Cr ( 2% Y-o-Y) ~USD 103 Mn Operating EBITDA margin 22% (27% in Q2 FY25) Reported PAT before exceptional

22%

y practices.. Revenue from Operations Rs 911 Cr ( 2% Y-o-Y) ~USD 103 Mn Operating EBITDA margin 22% (27% in Q2 FY25) Reported PAT before exceptional items : (-37%YoY) H1 FY26 Financial Highlights

27%

ctices.. Revenue from Operations Rs 911 Cr ( 2% Y-o-Y) ~USD 103 Mn Operating EBITDA margin 22% (27% in Q2 FY25) Reported PAT before exceptional items : (-37%YoY) H1 FY26 Financial Highlights Reven

37%

SD 103 Mn Operating EBITDA margin 22% (27% in Q2 FY25) Reported PAT before exceptional items : (-37%YoY) H1 FY26 Financial Highlights Revenue from Operations Rs 1,785 Cr ( 6% Y-o-Y) ~USD 204 Mn Op

Rs 1,785

ed PAT before exceptional items : (-37%YoY) H1 FY26 Financial Highlights Revenue from Operations Rs 1,785 Cr ( 6% Y-o-Y) ~USD 204 Mn Operating EBITDA margin 23% (25% in H1 FY25) Reported PAT before excep

6%

exceptional items : (-37%YoY) H1 FY26 Financial Highlights Revenue from Operations Rs 1,785 Cr ( 6% Y-o-Y) ~USD 204 Mn Operating EBITDA margin 23% (25% in H1 FY25) Reported PAT before exceptional

23%

Highlights Revenue from Operations Rs 1,785 Cr ( 6% Y-o-Y) ~USD 204 Mn Operating EBITDA margin 23% (25% in H1 FY25) Reported PAT before exceptional items : ( -4% YoY) Putting Science to Work 5 2

25%

lights Revenue from Operations Rs 1,785 Cr ( 6% Y-o-Y) ~USD 204 Mn Operating EBITDA margin 23% (25% in H1 FY25) Reported PAT before exceptional items : ( -4% YoY) Putting Science to Work 5 2 Syn

4%

D 204 Mn Operating EBITDA margin 23% (25% in H1 FY25) Reported PAT before exceptional items : ( -4% YoY) Putting Science to Work 5 2 Syngene – Putting Science to Work Partner in innovation: #Put

Rs. 5 Billion

olecules • Extension of collaboration with BMS; • Merger of Clinigene • Crossed annual turnover of Rs. 5 Billion Foundation • Operations started • Expansion of R&D Lab • Granted 100% EOU status by the Governme

Integrated services

1

IR Contact

1

Media Contact

1

Integrated services

• • • Manufacturing Research Services Development and for small/large molecules • • • • Product Based Biosimilars Formulations and Compounds Alternative Therapeutic Drugs Putting Science to Work 29 Shareholding and Share Information Syngene’s shareholders* 1% 47% Promoter & Promoter Group 53% Public ESOP Trust Syngene’s Share Information* NSE Ticker BSE Ticker Market Cap (Rs. Mn) % free-float^ Free-float market cap (Rs. Mn) Share Outstanding (Mn) SYNGENE 539268 2,50,971 47% 1,18,750 403 • As on 30th September 2025 • ^ Free float includes shares held by public and in ESOP Trust Putting Science to Work 30 For more details Visit our website www.syngeneintl.com https://www.linkedin.com/company/syngene-international-limited https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ

IR Contact

Nandini Agarwal / Shubham Jain +91 7838382527 / +91 6377651994 investor@syngeneintl.com nandini.agarwal@syngeneintl.com shubham.jain@syngeneintl.com